[go: up one dir, main page]

WO2002031209A3 - Genes related to development of refractory prostate cancer - Google Patents

Genes related to development of refractory prostate cancer Download PDF

Info

Publication number
WO2002031209A3
WO2002031209A3 PCT/US2001/031932 US0131932W WO0231209A3 WO 2002031209 A3 WO2002031209 A3 WO 2002031209A3 US 0131932 W US0131932 W US 0131932W WO 0231209 A3 WO0231209 A3 WO 0231209A3
Authority
WO
WIPO (PCT)
Prior art keywords
refractory prostate
prostate cancer
development
hormone
genes related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031932
Other languages
French (fr)
Other versions
WO2002031209A2 (en
Inventor
Spyro Mousses
Olli P Kallioniemi
Lukas Bubendorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU2002214576A priority Critical patent/AU2002214576A1/en
Publication of WO2002031209A2 publication Critical patent/WO2002031209A2/en
Anticipated expiration legal-status Critical
Publication of WO2002031209A3 publication Critical patent/WO2002031209A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides hormone-refractory prostate cancer (HPRC)-related nucleic acid molecules and proteins useful for the detection of neoplasms, particularly prostate and more specifically hormone-refractory prostate cancers. Also provided are methods of using these biological materials in the diagnosis, staging, detection, and treatment of neoplasia, and particularly hormone-refractory prostate cancer.
PCT/US2001/031932 2000-10-13 2001-10-12 Genes related to development of refractory prostate cancer Ceased WO2002031209A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214576A AU2002214576A1 (en) 2000-10-13 2001-10-12 Genes related to development of refractory prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24058500P 2000-10-13 2000-10-13
US60/240,585 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002031209A2 WO2002031209A2 (en) 2002-04-18
WO2002031209A3 true WO2002031209A3 (en) 2003-08-28

Family

ID=22907131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031932 Ceased WO2002031209A2 (en) 2000-10-13 2001-10-12 Genes related to development of refractory prostate cancer

Country Status (2)

Country Link
AU (1) AU2002214576A1 (en)
WO (1) WO2002031209A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526425A (en) * 2000-11-28 2004-09-02 ワイス Expression analysis of FKBP nucleic acids and polypeptides useful for diagnosis and treatment of prostate cancer
NZ526707A (en) * 2000-11-28 2005-03-24 Wyeth Corp Use of SMARC nucleic acid and polypeptide expression analysis for the diagnosis and prognosis of prostate cancer
US20030235816A1 (en) * 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
ITBZ20020040A1 (en) * 2002-10-11 2004-04-12 Saverio Bettuzzi METHOD FOR IDENTIFICATION THROUGH THE DESIGN AND USE OF APPROPRIATE MICROCHIP -DNA MICROARRAY OF THE TUMOR TRANSFORMATION OF THE PROSTATIC TISSUE, ASSESSMENT OF ITS MALIGNITY AND PROGNOSIS OF HUMAN PROSTATIC CANCER BY A NEW ME
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
WO2005083118A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Pin-prc transition genes
ES2550614T3 (en) 2004-04-09 2015-11-11 Genomic Health, Inc. Gene expression markers to predict the response to chemotherapy
EP2280084B1 (en) * 2004-12-02 2015-02-11 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US20120009581A1 (en) * 2008-07-08 2012-01-12 Bankaitis-Davis Danute M Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects
WO2010093872A2 (en) 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
ES2925983T3 (en) 2010-07-27 2022-10-20 Genomic Health Inc Method for using gene expression to determine prostate cancer prognosis
JP2012178990A (en) * 2011-02-28 2012-09-20 Soka Univ Method for detecting recurrent prostate cancer
CN102234631B (en) * 2011-04-29 2014-05-07 南方医科大学 Human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY03 and monoclonal antibody
CN102234633B (en) * 2011-04-29 2014-05-07 南方医科大学 Human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY02 and monoclonal antibody
CN102234632B (en) * 2011-04-29 2014-05-14 南方医科大学 Hybrid tumor DY01 of monoclonal antibody of human ubiquitin-conjugating enzyme UbcH10, and monoclonal antibody
NZ722902A (en) 2012-01-31 2017-12-22 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
US20150329912A1 (en) * 2013-01-13 2015-11-19 Emory University Biomarkers in cancer, methods, and systems related thereto
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2018022917A1 (en) * 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056910A1 (en) * 1997-06-11 1998-12-17 Chiron Corporation DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE
WO1999066051A2 (en) * 1998-06-16 1999-12-23 Sugen, Inc. Nek-related and bub1-related protein kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056910A1 (en) * 1997-06-11 1998-12-17 Chiron Corporation DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE
WO1999066051A2 (en) * 1998-06-16 1999-12-23 Sugen, Inc. Nek-related and bub1-related protein kinases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BUBENDORF L ET AL: "HORMONE THERAPY FAILURE IN HUMAN PROSTATE CANCER: ANALYSIS BY COMPLEMENTARY DNA AND TISSUE MICROARRAYS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 91, no. 20, 20 October 1999 (1999-10-20), pages 1758 - 1764, XP002934471, ISSN: 0027-8874 *
CARLISLE ALEX J ET AL: "Development of a prostate cDNA microarray and statistical gene expression analysis package.", MOLECULAR CARCINOGENESIS, vol. 28, no. 1, May 2000 (2000-05-01), pages 12 - 22, XP002225396, ISSN: 0899-1987 *
HOWELL S ET AL.: "DNA microarrays for analysis of gene expression in prostate cancer", MOLECULAR UROLOGY, vol. 3, no. 3, 1999, pages 295 - 302, XP001131993 *
MOUSSES S ET AL: "Functionnal genomics : gene expression analysis by cDNA microarrays", 2000, LIVESEY FJ AND HUNT SP (EDS) OXFORD UNIVERSITY PRESS, OXFORD, XP008011769 *
MOUSSES SPYRO ET AL: "Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.", ONCOGENE, vol. 20, no. 46, 11 October 2001 (2001-10-11), pages 6718 - 6723, XP001132000, ISSN: 0950-9232 *
NAKAJIMA HIDENORI ET AL: "New antitumor substances, FR901463, FR901464 and FR901465: II. Activities against experimental tumors in mice and mechanism of action.", JOURNAL OF ANTIBIOTICS (TOKYO), vol. 49, no. 12, 1996, pages 1204 - 1211, XP001109403, ISSN: 0021-8820 *
VAARALA M H ET AL: "Differentially expressed genes in two LNCaP prostate cancer cell lines", LABORATORY INVESTIGATION;A JOURNAL OF TECHNICAL METHODS AND PATHOLOGY. UNITED STATES AUG 2000, vol. 80, no. 8, August 2000 (2000-08-01), pages 1259 - 1268, XP002225395, ISSN: 0023-6837 *

Also Published As

Publication number Publication date
WO2002031209A2 (en) 2002-04-18
AU2002214576A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
WO2000028090A3 (en) Diagnostic assay for cancer
WO2007033187A3 (en) Recurrent gene fusions in prostate cancer
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2004056874A3 (en) Neuropilin-1 inhibitors
ATE229073T1 (en) PROTEIN E25A, METHODS OF ITS PRODUCTION AND APPLICATION
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2740100A (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2006036175A3 (en) Wnt proteins and detection and treatment of cancer
ATE491951T1 (en) TUMOR-SPECIFIC P450 PROTEIN
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2002055735A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2002064023A3 (en) Fra-1 expression in brain cancer
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP